TCGA-LGG Samples Report
2020_01_16 Data Snapshot
- Overview
+ Introduction
- Summary

There were 0 redactions, 0 replicate aliquots, 0 blacklisted aliquots, and 0 FFPE aliquots. The table below represents the sample counts for those samples that were ingested into firehose after filtering out redactions, replicates, and blacklisted data, and segregating FFPEs.

Table 1.  This table provides a breakdown of sample counts on a per sample type and, if applicable, per subtype basis. Each count is a link to a table containing a list of the samples that comprise that count and details pertaining to each individual sample (e.g. platform, sequencing center, etc.). Please note, there are usually multiple protocols per data type, so there are typically many more rows than the count implies.

Sample.Type BCR Clinical CN mRNA miR MAF Methylation
NBC 2 2 2 0 0 0 0
NB 486 484 486 0 0 0 0
TR 14 14 14 14 14 14 14
TP 516 514 515 511 512 513 515
Totals 516 514 515 511 512 513 515

The sample type short letter codes in the table above are defined in the following list.

  • TP: Primary Tumor

  • TR: Recurrent Tumor

  • TB: Primary Blood Derived Cancer - Peripheral Blood

  • TRBM: Recurrent Blood Derived Cancer - Bone Marrow

  • TAP: Additional - New Primary

  • TM: Metastatic

  • TAM: Additional Metastatic

  • THOC: Human Tumor Original Cells

  • TBM: Primary Blood Derived Cancer - Bone Marrow

  • NB: Blood Derived Normal

  • NT: Solid Tissue Normal

  • NBC: Buccal Cell Normal

  • NEBV: EBV Immortalized Normal

  • NBM: Bone Marrow Normal

  • CELLC: Control Analyte

  • TRB: Recurrent Blood Derived Cancer - Peripheral Blood

  • CELL: Cell Lines

  • XP: Primary Xenograft Tissue

  • XCL: Cell Line Derived Xenograft Tissue

Figure 1.  Get High-res Image This figure depicts the distribution of available data on a per participant basis.

- Results
+ Methods & Data